Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

Rabitsch W.; Bojic M.; Wohlfarth P.; Leiner M.; Schoergenhofer C.; Kalhs P.; Schulenburg A.; Sillaber C.; Mitterbauer M.; Sperr W. R.; Jaeger U.; Skrabs K.; Greinix H.; Hermann A.; Lamm W.

首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

【24h】

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

机译：Alemtuzumab-BEAM作为复发/难治性霍奇金淋巴瘤同种异体造血干细胞移植的条件：单中心分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Treatment of refractory Hodgkin disease deserves specific considerations. Recently, alemtuzumab-BEAM has been introduced in allogeneic hematopoietic stem cell transplantation (HSCT) in these patients.

机译：难治性霍奇金病的治疗值得特别考虑。最近，在这些患者的同种异体造血干细胞移植（HSCT）中引入了alemtuzumab-BEAM。

著录项

来源
《Journal of Cancer Research and Clinical Oncology》 |2016年第6期|共8页
作者
Rabitsch W.; Bojic M.; Wohlfarth P.; Leiner M.; Schoergenhofer C.; Kalhs P.; Schulenburg A.; Sillaber C.; Mitterbauer M.; Sperr W. R.; Jaeger U.; Skrabs K.; Greinix H.; Hermann A.; Lamm W.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Hodgkin lymphoma; Allogeneic HSCT; Alemtuzumab-BEAM;

机译：霍奇金淋巴瘤;同种异体HSCT;Alemtuzumab-BEAM;

相似文献

外文文献
中文文献
专利

1. Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis [J] . Rabitsch W., Bojic M., Wohlfarth P., Journal of Cancer Research and Clinical Oncology . 2016,第6期

机译：Alemtuzumab-BEAM作为复发/难治性霍奇金淋巴瘤同种异体造血干细胞移植的条件：单中心分析
2. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era [J] . Mussetti A., Devlin S. M., Castro-Malaspina H. R., Bone marrow transplantation . 2015,第10期

机译：成人非复发性同种异体造血干细胞移植治疗复发性和难治性套细胞淋巴瘤：利妥昔单抗时代的单中心分析
3. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [J] . Jeon Young-Woo, Yoon Seugyun, Min Gi June, Nature reviews Cancer . 2019,第6期

机译：氟甲滨和梅酚的临床结果，令人难以置力的或复发腐蚀性非霍奇金淋巴瘤患者800 CGY全身辐照调理方案，接受同种异体造血干细胞移植
4. Circulating Tumor DNA Predicts Post-Allogeneic Hematopoietic Stem Cell Transplantation in AML and MDS [C] . Sousuke Nakamura International Molecular Medicine Tri-Conference. . 2019

机译：循环肿瘤DNA预测AML和MDS中的同种异体造血干细胞移植
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis [O] . W. Rabitsch, M. Bojic, P. Wohlfarth, -1

机译：Alemtuzumab-BEAM作为复发/难治性霍奇金淋巴瘤同种异体造血干细胞移植的条件：单中心分析
7. Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis [O] . W. Rabitsch, M. Bojic, P. Wohlfarth, 2016

机译：Alemtuzumab-BEAM作为复发/难治性霍奇金淋巴瘤同种异体造血干细胞移植的条件：单中心分析

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

摘要

著录项

相似文献

相关主题

期刊订阅